Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Molecular targeting of renal inflammation using drug delivery technology to inhibit NF-κB improves renal recovery in chronic kidney disease

Molecular targeting of renal inflammation using drug delivery technology to inhibit NF-κB... Inflammation is a major determinant for the progression of chronic kidney disease (CKD). NF-κB is a master transcription factor upregulated in CKD that promotes inflammation and regulates apoptosis and vascular remodeling. We aimed to modulate this pathway for CKD therapy in a swine model of CKD using a peptide inhibitor of the NF-κB p50 subunit (p50i) fused to a protein carrier [elastin-like polypeptide (ELP)] and equipped with a cell-penetrating peptide (SynB1). We hypothesized that intrarenal SynB1-ELP-p50i therapy would inhibit NF-κB-driven inflammation and induce renal recovery. CKD was induced in 14 pigs. After 6 wk, pigs received single intrarenal SynB1-ELP-p50i therapy (10 mg/kg) or placebo (n = 7 each). Renal hemodynamics were quantified in vivo using multidetector computed tomography before and 8 wk after treatment. Pigs were then euthanized. Ex vivo experiments were performed to quantify renal activation of NF-κB, expression of downstream mediators of NF-κB signaling, renal microvascular density, inflammation, and fibrosis. Fourteen weeks of CKD stimulated NF-κB signaling and downstream mediators (e.g., TNF-α, monocyte chemoattractant protein-1, and IL-6) accompanying loss of renal function, inflammation, fibrosis, and microvascular rarefaction versus controls. All of these were improved after SynB1-ELP-p50i therapy, accompanied by reduced circulating inflammatory cytokines as well, which were evident up to 8 wk after treatment. Current treatments for CKD are largely ineffective. Our study shows the feasibility of a new treatment to induce renal recovery by offsetting inflammation at a molecular level. It also supports the therapeutic potential of targeted inhibition of the NF-κB pathway using novel drug delivery technology in a translational model of CKD. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Physiology-Renal Physiology The American Physiological Society

Molecular targeting of renal inflammation using drug delivery technology to inhibit NF-κB improves renal recovery in chronic kidney disease

Download PDF
10 pages

Loading next page...
 
/lp/the-american-physiological-society/molecular-targeting-of-renal-inflammation-using-drug-delivery-M8g2lc4k6U

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1931-857x
eISSN
1522-1466
DOI
10.1152/ajprenal.00155.2020
Publisher site
See Article on Publisher Site

Abstract

Inflammation is a major determinant for the progression of chronic kidney disease (CKD). NF-κB is a master transcription factor upregulated in CKD that promotes inflammation and regulates apoptosis and vascular remodeling. We aimed to modulate this pathway for CKD therapy in a swine model of CKD using a peptide inhibitor of the NF-κB p50 subunit (p50i) fused to a protein carrier [elastin-like polypeptide (ELP)] and equipped with a cell-penetrating peptide (SynB1). We hypothesized that intrarenal SynB1-ELP-p50i therapy would inhibit NF-κB-driven inflammation and induce renal recovery. CKD was induced in 14 pigs. After 6 wk, pigs received single intrarenal SynB1-ELP-p50i therapy (10 mg/kg) or placebo (n = 7 each). Renal hemodynamics were quantified in vivo using multidetector computed tomography before and 8 wk after treatment. Pigs were then euthanized. Ex vivo experiments were performed to quantify renal activation of NF-κB, expression of downstream mediators of NF-κB signaling, renal microvascular density, inflammation, and fibrosis. Fourteen weeks of CKD stimulated NF-κB signaling and downstream mediators (e.g., TNF-α, monocyte chemoattractant protein-1, and IL-6) accompanying loss of renal function, inflammation, fibrosis, and microvascular rarefaction versus controls. All of these were improved after SynB1-ELP-p50i therapy, accompanied by reduced circulating inflammatory cytokines as well, which were evident up to 8 wk after treatment. Current treatments for CKD are largely ineffective. Our study shows the feasibility of a new treatment to induce renal recovery by offsetting inflammation at a molecular level. It also supports the therapeutic potential of targeted inhibition of the NF-κB pathway using novel drug delivery technology in a translational model of CKD.

Journal

American Journal of Physiology-Renal Physiology – The American Physiological Society

Published: Jul 1, 2020

References

  • Inflammation and progression of CKD: the CRIC study
    Amdur, RL; Feldman, HI; Gupta, J; Yang, W; Kanetsky, P; Shlipak, M; Rahman, M; Lash, JP; Townsend, RR; Ojo, A; Roy-Chaudhury, A; Go, AS; Joffe, M; He, J; Balakrishnan, VS; Kimmel, PL; Kusek, JW; Raj, DS
  • NF-kappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement
    Aurora, AB; Biyashev, D; Mirochnik, Y; Zaichuk, TA; Sánchez-Martinez, C; Renault, MA; Losordo, D; Volpert, OV
  • Arterial and cellular inflammation in patients with CKD
    Bernelot Moens, SJ; Verweij, SL; van der Valk, FM; van Capelleveen, JC; Kroon, J; Versloot, M; Verberne, HJ; Marquering, HA; Duivenvoorden, R; Vogt, L; Stroes, ES
  • A kidney-selective biopolymer for targeted drug delivery
    Bidwell, GL; Mahdi, F; Shao, Q; Logue, OC; Waller, JP; Reese, C; Chade, AR
  • Divergent effects of AKI to CKD models on inflammation and fibrosis
    Black, LM; Lever, JM; Traylor, AM; Chen, B; Yang, Z; Esman, SK; Jiang, Y; Cutter, GR; Boddu, R; George, JF; Agarwal, A
  • Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 1/2 years
    Bosmans, JL; Holvoet, P; Dauwe, SE; Ysebaert, DK; Chapelle, T; Jürgens, A; Kovacic, V; Van Marck, EA; De Broe, ME; Verpooten, GA
  • Endothelin-1 receptor blockade prevents renal injury in experimental hypercholesterolemia
    Chade, AR; Best, PJ; Rodriguez-Porcel, M; Herrmann, J; Zhu, X; Sawamura, T; Napoli, C; Lerman, A; Lerman, LO
  • Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia
    Chade, AR; Herrmann, J; Zhu, X; Krier, JD; Lerman, A; Lerman, LO
  • Renal microvascular disease determines the responses to revascularization in experimental renovascular disease
    Chade, AR; Kelsen, S
  • Reversal of renal dysfunction by targeted administration of VEGF into the stenotic kidney: a novel potential therapeutic approach
    Chade, AR; Kelsen, S
  • Distinct renal injury in early atherosclerosis and renovascular disease
    Chade, AR; Rodriguez-Porcel, M; Grande, JP; Krier, JD; Lerman, A; Romero, JC; Napoli, C; Lerman, LO
  • Antioxidant intervention blunts renal injury in experimental renovascular disease
    Chade, AR; Rodriguez-Porcel, M; Herrmann, J; Zhu, X; Grande, JP; Napoli, C; Lerman, A; Lerman, LO
  • Endothelin-a receptor antagonism after renal angioplasty enhances renal recovery in renovascular disease
    Chade, AR; Tullos, N; Stewart, NJ; Surles, B
  • Renal therapeutic angiogenesis using a bioengineered polymer-stabilized vascular endothelial growth factor construct
    Chade, AR; Tullos, NA; Harvey, TW; Mahdi, F; Bidwell, GL
  • A translational model of chronic kidney disease in swine
    Chade, AR; Williams, ML; Engel, J; Guise, E; Harvey, TW
  • Systemic biopolymer-delivered vascular endothelial growth factor promotes therapeutic angiogenesis in experimental renovascular disease
    Chade, AR; Williams, ML; Guise, E; Vincent, LJ; Harvey, TW; Kuna, M; Mahdi, F; Bidwell, GL
  • Endothelial progenitor cells restore renal function in chronic experimental renovascular disease
    Chade, AR; Zhu, X; Lavi, R; Krier, JD; Pislaru, S; Simari, RD; Napoli, C; Lerman, A; Lerman, LO
  • Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia
    Chade, AR; Zhu, X; Mushin, OP; Napoli, C; Lerman, A; Lerman, LO; Chade, AR; Zhu, X; Mushin, OP; Napoli, C; Lerman, A; Lerman, LO
  • Regulation of NF-κB by ubiquitination
    Chen, J; Chen, ZJ
  • Selective induction of MCP-1 in human mesangial cells by the IL-6/sIL-6R complex
    Coletta, I; Soldo, L; Polentarutti, N; Mancini, F; Guglielmotti, A; Pinza, M; Mantovani, A; Milanese, C
  • Assessment of renal hemodynamics and function in pigs with 64-section multidetector CT: comparison with electron-beam CT
    Daghini, E; Primak, AN; Chade, AR; Krier, JD; Zhu, XY; Ritman, EL; McCollough, CH; Lerman, LO
  • Endostatin induces endothelial cell apoptosis
    Dhanabal, M; Ramchandran, R; Waterman, MJ; Lu, H; Knebelmann, B; Segal, M; Sukhatme, VP
  • Albuminuria induces a proinflammatory and profibrotic response in cortical collecting ducts via the 24p3 receptor
    Dizin, E; Hasler, U; Nlandu-Khodo, S; Fila, M; Roth, I; Ernandez, T; Doucet, A; Martin, PY; Feraille, E; de Seigneux, S
  • Role of NFkappaB in age-related vascular endothelial dysfunction in humans
    Donato, AJ; Pierce, GL; Lesniewski, LA; Seals, DR
  • Albumin induces NF-kappaB expression in human proximal tubule-derived cells (IHKE-1)
    Drumm, K; Bauer, B; Freudinger, R; Gekle, M
  • A biopolymer-delivered, maternally sequestered NF-kB inhibitory peptide for treatment of preeclampsia
    Eddy, A; Howell, JA; Chapman, H
  • Targeted VEGF (vascular endothelial growth factor) therapy induces long-term renal recovery in chronic kidney disease via macrophage polarization
    Engel, JE; Williams, E; Williams, ML; Bidwell, GL; Chade, AR
  • Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways
    Eriksson, K; Magnusson, P; Dixelius, J; Claesson-Welsh, L; Cross, MJ
  • Regulation of NF-κB by TNF family cytokines
    Hayden, MS; Ghosh, S
  • Progressive renal vascular proliferation and injury in obese Zucker rats
    Iliescu, R; Chade, AR
  • Role of renal microcirculation in experimental renovascular disease
    Iliescu, R; Fernandez, SR; Kelsen, S; Maric, C; Chade, AR
  • Noninvasive measurement of concurrent single-kidney perfusion, glomerular filtration, and tubular function
    Krier, JD; Ritman, EL; Bajzer, Z; Romero, JC; Lerman, A; Lerman, LO
  • The nuclear factor NF-kappaB pathway in inflammation
    Lawrence, T
  • Noninvasive evaluation of a novel swine model of renal artery stenosis
    Lerman, LO; Schwartz, RS; Grande, JP; Sheedy, PF; Romero, JC
  • Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence
    Lin, YZ; Yao, SY; Veach, RA; Torgerson, TR; Hawiger, J
  • NF-κB signaling in inflammation
    Liu, T; Zhang, L; Joo, D; Sun, S-C
  • Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications
    López-Novoa, JM; Rodríguez-Peña, AB; Ortiz, A; Martínez-Salgado, C; López Hernández, FJ
  • Recombinant adeno-associated virus-delivered anginex inhibits angiogenesis and growth of HUVECs by regulating the Akt, JNK and NF-κB signaling pathways
    Ma, K; Wang, C; Geng, Q; Fan, Y; Ning, J; Yang, H; Dong, X; Dong, D; Guo, Y; Wei, X; Li, E; Wu, Y
  • Renal upregulation of HO-1 reduces albumin-driven MCP-1 production: implications for chronic kidney disease
    Murali, NS; Ackerman, AW; Croatt, AJ; Cheng, J; Grande, JP; Sutor, SL; Bram, RJ; Bren, GD; Badley, AD; Alam, J; Nath, KA
  • Quantitative imaging assay for NF-kappaB nuclear translocation in primary human macrophages
    Noursadeghi, M; Tsang, J; Haustein, T; Miller, RF; Chain, BM; Katz, DR
  • Resolution of renal inflammation: a new role for NF-κB1 (p50) in inflammatory kidney diseases
    Panzer, U; Steinmetz, OM; Turner, JE; Meyer-Schwesinger, C; von Ruffer, C; Meyer, TN; Zahner, G; Gómez-Guerrero, C; Schmid, RM; Helmchen, U; Moeckel, GW; Wolf, G; Stahl, RA; Thaiss, F
  • Awareness of chronic kidney disease among patients and providers
    Plantinga, LC; Tuot, DS; Powe, NR
  • UpToDate. Overview of the Management of Chronic Kidney Disease in Adults
    Rosenberg, M
  • NF-kappaB in renal inflammation
    Sanz, AB; Sanchez-Niño, MD; Ramos, AM; Moreno, JA; Santamaria, B; Ruiz-Ortega, M; Egido, J; Ortiz, A
  • US renal data system 2017 annual data report: epidemiology of kidney disease in the United States
    Saran, R; Robinson, B; Abbott, KC; Agodoa, LYC; Bhave, N; Bragg-Gresham, J; Balkrishnan, R; Dietrich, X; Eckard, A; Eggers, PW; Gaipov, A; Gillen, D; Gipson, D; Hailpern, SM; Hall, YN; Han, Y; He, K; Herman, W; Heung, M; Hirth, RA; Hutton, D; Jacobsen, SJ; Jin, Y; Kalantar-Zadeh, K; Kapke, A; Kovesdy, CP; Lavallee, D; Leslie, J; McCullough, K; Modi, Z; Molnar, MZ; Montez-Rath, M; Moradi, H; Morgenstern, H; Mukhopadhyay, P; Nallamothu, B; Nguyen, DV; Norris, KC; O’Hare, AM; Obi, Y; Park, C; Pearson, J; Pisoni, R; Potukuchi, PK; Rao, P; Repeck, K; Rhee, CM; Schrager, J; Schaubel, DE; Selewski, DT; Shaw, SF; Shi, JM; Shieu, M; Sim, JJ; Soohoo, M; Steffick, D; Streja, E; Sumida, K; Tamura, MK; Tilea, A; Tong, L; Wang, D; Wang, M; Woodside, KJ; Xin, X; Yin, M; You, AS; Zhou, H; Shahinian, V
  • Immune cells and inflammation in AKI to CKD progression
    Sato, Y; Yanagita, M
  • Angiotensin II increases angiogenesis by NF-κB-mediated transcriptional activation of angiogenic factor AGGF1
    Si, W; Xie, W; Deng, W; Xiao, Y; Karnik, SS; Xu, C; Chen, Q; Wang, QK
  • NFkappaB and kidney injury
    Song, N; Thaiss, F; Guo, L
  • Saturated, but not unsaturated, fatty acids induce apoptosis of human coronary artery endothelial cells via nuclear factor-kappaB activation
    Staiger, K; Staiger, H; Weigert, C; Haas, C; Häring, HU; Kellerer, M
  • Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure
    Stenvinkel, P; Heimbürger, O; Paultre, F; Diczfalusy, U; Wang, T; Berglund, L; Jogestrand, T
  • Inhibition of the NF-κB signaling pathway on endothelial cell function and angiogenesis in mice with acute cerebral infarction
    Sui, X
  • Enhanced MCP-1 expression during ischemia/reperfusion injury is mediated by oxidative stress and NF-kappaB
    Sung, FL; Zhu, TY; Au-Yeung, KK; Siow, YL; O, K
  • A thermally targeted carrier of p50 NLS peptide inhibits cancer cell proliferation by preventing NFκB nuclear translocation
    Thomas, EH; Raucher, D
  • Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease
    Tullos, NA; Stewart, NJ; Davidovich, R; Chade, AR
  • Variation in patients’ awareness of CKD according to how they are asked
    Tuot, DS; Zhu, Y; Velasquez, A; Espinoza, J; Mendez, CD; Banerjee, T; Hsu, CY; Powe, NR
  • Oxidized LDLs alter the activity of the ubiquitin-proteasome pathway: potential role in oxidized LDL-induced apoptosis
    Vieira, O; Escargueil-Blanc, I; Jürgens, G; Borner, C; Almeida, L; Salvayre, R; Nègre-Salvayre, A
  • Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide
    Wang, S; Kotamraju, S; Konorev, E; Kalivendi, S; Joseph, J; Kalyanaraman, B
  • Effects of ROS-relative NF-κB signaling on high glucose-induced TLR4 and MCP-1 expression in podocyte injury
    Wei, M; Li, Z; Xiao, L; Yang, Z
  • The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension
    Zhu, XY; Chade, AR; Krier, JD; Daghini, E; Lavi, R; Guglielmotti, A; Lerman, A; Lerman, LO
  • Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
    Zimmermann, J; Herrlinger, S; Pruy, A; Metzger, T; Wanner, C